We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

ASSIST Registry Studying Various Operator Techniques

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03845491
Recruitment Status : Completed
First Posted : February 19, 2019
Last Update Posted : April 13, 2023
Sponsor:
Information provided by (Responsible Party):
Stryker Neurovascular

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this Registry is to assess the procedural success and clinical outcomes associated with various operator techniques for mechanical thrombectomy in large vessel occlusions (LVO).

Condition or disease Intervention/treatment
Ischemic Stroke Device: Mechanical Thrombectomy

Detailed Description:
ASSIST is a prospective, global, consecutive enrollment Registry of anterior circulation acute ischemic stroke patients with an LVO who undergo treatment with one of the interventional techniques using Stryker Neurovascular devices for the first pass. The purpose of this Registry is to assess the procedural success and clinical outcomes associated with various operator techniques for mechanical thrombectomy in large vessel occlusions (LVO) in the anterior circulation. Data will be collected on the use of Stryker market-released neurovascular mechanical access and mechanical thrombectomy devices that are commercially available or that may be approved for commercial use during the conduct of the Registry. This Registry will also collect data, including time-to-treatment and quality of life measures, to allow for subset analyses.
Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational [Patient Registry]
Actual Enrollment : 1500 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 90 Days
Official Title: ASSIST Registry to Assess the Procedural Success and Clinical Outcomes Associated With Various Operator Techniques for Mechanical Thrombectomy in Large Vessel Occlusions (LVO).
Actual Study Start Date : January 23, 2019
Actual Primary Completion Date : May 11, 2022
Actual Study Completion Date : January 25, 2023
Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
SR Classic
SR (Trevo®]) + BGC (FlowGate2] or Merci)
 Device: Mechanical Thrombectomy
Treatment of LVO with mechanical thrombectomy
SR Combination

SR (Trevo) + Asp Cath (AXS Catalyst DAC, Vecta) ± Pump

+ LS (AXS Infinity LS, AXS Infinity LS Plus)

or

SR (Trevo) + Asp Cath (AXS Catalyst DAC) ± Pump + BGC (FlowGate2 or Merci)

 Device: Mechanical Thrombectomy
Treatment of LVO with mechanical thrombectomy
Direct Aspiration

Asp Cath (AXS Catalyst DAC, Vecta) ± Pump + LS (AXS Infinity LS, AXS Infinity LS Plus)

or

Asp Cath (AXS Catalyst DAC) ± Pump + BGC (FlowGate2, Merci)

 Device: Mechanical Thrombectomy
Treatment of LVO with mechanical thrombectomy


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Severity of disability at Day 90 assessed by modified Rankin Scale (mRS) with a good functional outcome defined by mRS score. [ Time Frame: 90 Days ]
    Severity of disability at Day 90 (± 14) assessed by modified Rankin Scale (mRS) with a good functional outcome defined as mRS of 0-2 for each technique.


Secondary Outcome Measures :
  1. Proportion of subjects with an excellent functional outcome at Day 90 [ Time Frame: 90 Days ]
    Proportion of subjects with an excellent functional outcome of mRS of 0-1 at Day 90 (± 14)

  2. Proportion of subjects with an "early response" defined by NIHSS score [ Time Frame: Discharge/ Day 5-7 (Whichever is earlier) ]
    Proportion of subjects with an "early response" at Discharge/Day5-7 (whichever is earlier) defined as a NIHSS drop of ≥10 points from baseline or NIHSS score of 0 or 1

  3. Quality of Life at day 90 based on EQ5D5L score [ Time Frame: Day 90 ]
    Quality of Life at Day 90 (± 14) assessed by EuroQoL (EQ5D5L)


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Subjects experiencing acute ischemic stroke (AIS) who are eligible for restoration of blood flow using Stryker Neurovascular market-released products in the neurovasculature to remove thrombus
Criteria

Inclusion Criteria:

  • Subjects experiencing acute ischemic stroke (AIS) who are eligible for restoration of blood flow using Stryker Neurovascular market-released products in the neurovasculature to remove thrombus
  • Occlusion of intracranial anterior circulation vessel
  • Subject or subject's legally authorized representative (LAR) has signed the informed consent form prior to or within 48 hours post-procedure
  • Subject is willing to comply with the protocol follow-up requirements
  • Subject is treated using at least one of the defined techniques for the first pass in the neurovasculature to remove thrombus.

Exclusion Criteria:

  • The subject is participating in another device trial or any other clinical trial where the study procedure or treatment might confound this study's endpoint.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03845491


Locations
Show Show 72 study locations
Sponsors and Collaborators
Stryker Neurovascular
Investigators
Layout table for investigator information
Principal Investigator: Rishi Gupta, MD WellStar Medical Group
Principal Investigator: Markus Möhlenbruch, MD University Hospital Heidelberg
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Additional Information:

Layout table for additonal information
Responsible Party: Stryker Neurovascular
ClinicalTrials.gov Identifier: NCT03845491    
Other Study ID Numbers: CDM10001414
First Posted: February 19, 2019    Key Record Dates
Last Update Posted: April 13, 2023
Last Verified: April 2023

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Ischemic Stroke
Stroke
Cerebrovascular Disorders
Brain Diseases
 Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases